YK11 | Advanced Myostatin Inhibitor & SARM
$79.00
YK11 is a unique, synthetic research compound often categorized as a Selective Androgen Receptor Modulator (SARM), though its chemical structure closely resembles that of a steroidal nucleus. In advanced musculoskeletal research, YK11 is distinguished by its dual mechanism: it acts as a partial agonist of the androgen receptor and, more significantly, as a potent inducer of Follistatin production. This dual-action pathway makes it a primary subject for studying the circumvention of genetic muscle-growth limitations through myostatin inhibition.
YK11: The Science of Follistatin Induction and Myostatin Blockade
The Biochemistry of YK11
YK11 ($C_{25}H_{34}O_{6}$) is structurally unique among SARMs, possessing a 19-norsteroidal backbone. In laboratory settings, it has demonstrated the ability to bind to the androgen receptor with high selectivity. However, unlike traditional SARMs that focus solely on androgenic signaling, YK11‘s most notable characteristic is its ability to stimulate the expression of Follistatin, a naturally occurring protein that inhibits myostatin.
Mechanism of Action: Dual Anabolic Signaling
In advanced pharmacology and muscle physiology research, YK11 functions through several coordinated pathways:
-
Follistatin Expression: The compound is investigated for its ability to significantly increase Follistatin levels in muscle cells. Follistatin binds to and neutralizes myostatin, a protein that typically limits muscle tissue growth.
-
Myostatin Inhibition: By increasing Follistatin, YK11 provides a model for researching “myostatin-deficient” phenotypes, which exhibit vastly accelerated muscle cell proliferation and differentiation.
-
Androgen Receptor Agonism: YK11 acts as a partial agonist at the androgen receptor, contributing to anabolic signaling pathways similarly to other SARMs, but with a unique steroidal-like affinity.
-
Selective Muscle Hypertrophy: Research focuses on the compound’s potential to drive muscle growth beyond the biological ceiling imposed by endogenous myostatin levels.
Primary Research Applications
-
Myostatin Antagonism Studies: Analyzing the cellular mechanisms of how Follistatin induction bypasses the regulatory “brakes” on muscle growth.
-
Sarcopenia and Degenerative Modeling: Investigating the restoration of lean tissue in models where muscle wasting is driven by high myostatin activity.
-
Bone Mineralization Research: Studying the secondary effects of YK11 on osteoblast activity and the potential for increasing bone strength.
-
Cellular Differentiation: Observing how the compound influences the transition of satellite cells into functional muscle fibers.
4. Technical Specifications (E-E-A-T Data)
| Feature | Scientific Specification |
| Chemical Name | Methyl (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylate |
| Molecular Formula | $C_{25}H_{34}O_{6}$ |
| Molecular Weight | 430.5 g/mol |
| CAS Number | 1370003-76-1 |
| Purity Grade | $\geq$99% (HPLC Verified) |
| Form | Research Grade Tablets (10mg Standardized) |
| Solubility | Soluble in DMSO and Ethanol |
5. Product FAQ
Q: Is YK11 a SARM or a steroid?
A: YK11 is often classified as a SARM because it selectively targets the androgen receptor. However, because its chemical structure is based on a steroidal nucleus, it is frequently referred to as a “SARM-steroid hybrid” in research literature.
Q: Why is Follistatin important in YK11 research?
A: Follistatin is the body’s natural inhibitor of myostatin. Since myostatin limits how much muscle a subject can grow, YK11 is researched for its ability to boost Follistatin, effectively allowing muscle growth to exceed typical genetic limits in laboratory models.
Related products
GLP-1 & METABOLIC RESEARCH COMPOUNDS
GIP Peptide | Gastric Inhibitory Polypeptide Research Analysis
GLP-1 & METABOLIC RESEARCH COMPOUNDS
RESEARCH-GRADE COMPOUNDS
RESEARCH-GRADE COMPOUNDS
GLP-1 & METABOLIC RESEARCH COMPOUNDS
